Full Press Release Details
CureVac and Novartis Sign Initial Agreement on Manufacturing
of COVID-19 Vaccine Candidate, CVnCoV
T BINGEN, Germany/ BOSTON, USA - March 04, 2021
- CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines
based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the
manufacturing of CureVac's COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers
and test runs are already underway. Following final agreement, Novartis plans to manufacture the mRNA and bulk drugproduct of the
CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery
from the manufacturing site in Kundl, Austria, is expected to start in summer 2021.
Dr. Florian von der M lbe, Chief Production Officer of
CureVac, says: "I am very pleased that with Novartis we have found another highly experienced partner to support the production
of our vaccine candidate. Together with Novartis we expect to increase significantly our manufacturing capacity and place our production
network on an even broader base."
Steffen Lang, Global Head of Novartis Technical Operations and
member of Executive Committee Novartis, adds: "We feel it is our responsibility to do everything in our power to help and
we are pleased to announce our collaboration with CureVac. At the Kundl site, Novartis is a pioneer and has decades of experience
in pharmaceutical production of proteins and in more recent years of nucleic acids. We are currently expanding our site with additional
capacities for the production of mRNA in order to best serve the increasing demand."
CureVac started building an integrated European vaccine manufacturing
network with several CDMO partners in the fall of 2020. So far, CureVac is working with Bayer, Fareva, Wacker and Rentschler, among
development of its mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen first for clinical
development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike
protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a clinical trials of CVnCoV
began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was
generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T
cell activation. The quality of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune
response after natural COVID-19 infection. In December 2020 CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a
12 g dose of CVnCoV. In February 2021 CureVac initiated a rolling submission with the
European Medicines Agency (EMA) for CVnCoV.
CureVac has entered into
several strategic partnerships for the further development, production and commercialization of CVnCoV. The company entered into
a collaboration agreement with Bayer in January 2021 with regards to CureVac s current vaccine candidate CVnCoV. In February
2021 CureVac and the British pharmaceutical company GlaxoSmithKline (GSK) agreed to jointly develop next-generation multi-valent
mRNA vaccines against COVID-19. The development of new vaccine candidates is strengthened by a partnership with the UK Government
and its Vaccines Taskforce, which CureVac also entered in February 2021. GSK will also potentially contribute to this collaboration.
Clinical trial and commercial material is provided by the company's substantial production capacities for mRNA vaccines at
its headquarters in T bingen, supported by the current expansion of manufacturing capacities in Europe, allowing broad-scale
manufacturing of CVnCoV for potential commercial supply preparedness.
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise
in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology
is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of
fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across
the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its
initial public offering on the New York Nasdaq in August 2020. It is headquartered in T bingen, Germany, and employs more
than 600 people at its sites in T bingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.
CureVac Media Contact
Thorsten Sch ller, Vice President Communications
CureVac, T bingen, Germany
T: +49 7071 9883-1577
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, T bingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
Forward-Looking Statements
This press release contains statements that constitute "forward
looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including
statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the "company")
regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion
of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing
plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such
as "anticipate," "intend," "believe," "estimate," "plan," "seek,"
"project," or "expect," "may," "will," "would," "could,"
"potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the company.
However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue
reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances,
including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability
to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty
of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture
any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing
competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business
and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability
to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such
statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially
from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof.
The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce
the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's
reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR
on the SEC website at www.sec.gov